Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on EquityReturn on Sales

BioScience Health Innovations (BHIC) Debt to Equity (2019 - 2022)

Historic Debt to Equity for BioScience Health Innovations (BHIC) over the last 4 years, with Q2 2022 value amounting to $0.38.

  • BioScience Health Innovations' Debt to Equity rose 11964.41% to $0.38 in Q2 2022 from the same period last year, while for May 2022 it was $0.38, marking a year-over-year increase of 11964.41%. This contributed to the annual value of -$1.36 for FY2021, which is 32354.91% down from last year.
  • BioScience Health Innovations' Debt to Equity amounted to $0.38 in Q2 2022, which was up 11964.41% from $0.05 recorded in Q1 2022.
  • Over the past 5 years, BioScience Health Innovations' Debt to Equity peaked at $3.22 during Q4 2019, and registered a low of -$239.04 during Q1 2020.
  • Over the past 4 years, BioScience Health Innovations' median Debt to Equity value was $0.05 (recorded in 2022), while the average stood at -$21.72.
  • As far as peak fluctuations go, BioScience Health Innovations' Debt to Equity crashed by 36901.31% in 2021, and later surged by 11964.41% in 2022.
  • Quarter analysis of 4 years shows BioScience Health Innovations' Debt to Equity stood at $3.22 in 2019, then plummeted by 39.48% to $1.95 in 2020, then crashed by 87.76% to $0.24 in 2021, then soared by 57.49% to $0.38 in 2022.
  • Its last three reported values are $0.38 in Q2 2022, $0.05 for Q1 2022, and $0.24 during Q4 2021.